Medline Inc.MDLN
Medline Inc. Financial Overview 2025–2025
Updated Jul 10, 2026Despite delivering 10.7% revenue growth to reach $7.35 billion in Q1 2026, Medline saw its net income plunge 25.8% to $239 million, exposing an immediate vulnerability to rising import costs. The core thesis for investors is clear: while Medline’s distribution network and Prime Vendor relationships drive top-line expansion, escalating tariff hits and rising operational expenses are severely compressing bottom-line profitability.
The company's top-line trajectory remains intact, with net sales growing from $25.47 billion in FY2024 to $28.4 billion in FY2025. This scale is anchored by over 1,600 Prime Vendor partnerships, generating $18.0 billion in annual revenue. Yet margin pressure is acute. Tariffs erased $290 million from pre-tax income in FY2025. By Q1 2026, Cost of Goods Sold surged 14.3% alongside a 14.8% jump in selling, general, and administrative expenses. Offsetting this operational squeeze, Medline aggressively optimized its balance sheet following its initial public offering in December 2025. Using offering proceeds to pay down debt, the company slashed its Q1 2026 net interest expense by 35.2% to $136 million.
At the close of FY2025, the market priced Medline at $42.00 per share, looking past a negative $-0.01 earnings per share as investors prioritized debt reduction and top-line scaling. Armed with $2.24 billion in cash at the end of Q1 2026, Medline holds ample liquidity to navigate near-term supply chain friction.
Recent Developments (Q4 2025 and Q1 2026)
Medline extended its debt maturities in June 2026, issuing $2.0 billion in senior secured notes and securing a new $2.75 billion term loan due 2033 to manage its $12.76 billion debt burden. Operationally, the Supply Chain Solutions segment accelerated, jumping from 13.2% revenue growth in FY2025 to a 15.0% increase in Q1 2026, reaching $3.89 billion. Conversely, Medline Brand segment adjusted EBITDA contracted 7.8% in Q1 2026, despite generating a 6.2% revenue increase to $3.47 billion. Selling stockholders also offloaded 72.5 million shares at $37.00 each in June 2026.
Bulls see the extended debt maturities and sustained supply chain volumes as long-term margin catalysts. Bears warn that insider share sales and contracting brand profitability signal deeper operational headwinds. Priced at $42.01 on May 6, 2026, the stock lacks a calculable positive P/E ratio, appearing richly valued relative to current earnings performance.
What to watch: brand segment margin recovery; integration of the new term loan facility
Rev
$28.43B
FY2025
NI
$1.16T
FY2025
EPS
$-0.01
FY2025
OCF
$1.74B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Medline Inc. 8-K Report, Executive Changes (Jul 9, 2026)
Medline Inc. (MDLN) filed an 8-K on July 9, 2026, to report the upcoming retirement of its Chief Operating Officer (COO), Stephen L. Miller, effective August 30, 2026. The company cited health-related reasons for Mr. Miller's departure. Medline Inc. has initiated a search process to identify and appoint a successor to this key executive role. This announcement marks a significant change in the company's senior leadership. Investors should monitor the selection of the new COO, as this individual will play a crucial role in executing Medline's operational strategies and future growth initiatives. The transition timeline allows for a structured handover, but the market will likely be keen to understand the company's plans for ensuring operational continuity and a smooth leadership transition during this period.
Medline Inc. 8-K Report, Shareholder Vote Results (Jun 12, 2026)
Medline Inc. (MDLN) filed an 8-K on June 12, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. The primary outcomes include the election of all 12 director nominees, overwhelming approval of the Company's executive compensation on an advisory basis, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Importantly, stockholders also approved holding advisory votes on executive compensation annually.
Medline Inc. 8-K Report, Material Agreement (Jun 2, 2026)
Medline Inc. (MDLN) has filed an 8-K report detailing significant refinancing transactions executed on May 28, 2026. The company successfully issued $2.0 billion in aggregate principal amount of new senior secured notes, comprising $1.25 billion of 5.000% notes due 2031 and $750 million of 5.250% notes due 2033. These proceeds, along with new term loan borrowings and cash on hand, were utilized to repay existing debt, including a senior secured term loan due 2028 and a portion of its 2030 term loan facility, as well as to redeem a portion of its 2029 senior secured notes. This strategic move aims to extend debt maturities, potentially lower interest costs, and improve its overall debt structure. In parallel, Medline also amended its credit agreement to refinance its existing senior secured term loan facility due 2030 with a new approximately $2.75 billion senior secured dollar-denominated term loan facility due 2033. The company also announced a public offering of Class A common stock by certain selling stockholders, raising approximately $2.68 billion. While the debt transactions focus on capital structure optimization, the equity offering reflects potential liquidity events for major shareholders.
Medline Inc. 8-K Report, Financial Results (May 6, 2026)
Medline Inc. (MDLN) filed an 8-K on May 6, 2026, to report its financial results for the first quarter ended March 28, 2026. The filing primarily directs investors to an accompanying earnings press release (Exhibit 99.1) for detailed financial performance and operational updates. Investors should refer to this press release for specific figures on revenue, profitability, and any forward-looking statements or management commentary. While the 8-K itself does not contain the financial data, its purpose is to officially announce the release of these results, making them publicly available. The information provided is considered 'furnished' rather than 'filed,' which has implications under SEC regulations regarding liability for forward-looking statements. Investors seeking a comprehensive understanding of Medline's current financial health and outlook should carefully review the press release referenced in this filing.
Medline Inc. 8-K Report, Financial Results (Feb 25, 2026)
Medline Inc. (MDLN) has filed a Form 8-K on February 25, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. While the 8-K itself does not contain the detailed financial figures, it formally announces that Medline has issued an earnings press release containing this information, which is furnished as Exhibit 99.1 to this filing. Investors should refer to the press release (Exhibit 99.1) for specific details on Medline's performance. This filing serves as the official notification of the release of these results, indicating that key metrics such as revenue, profitability, and any significant year-over-year changes are now publicly available through the attached press release. The company is providing this update in compliance with SEC regulations regarding the disclosure of material financial information.
View all 8-K filings →